Follicular Lymphoma Clinical Trials

The following clinical trials are currently open and accruing for patients with follicular lymphoma.

Contact Kalin Morrell (Assistant Clinical Research Manager),
kalin_morrell@dfci.harvard.edu, 617-582-8713 to discuss a patient.

TRIALS FOR RELAPSED/REFRACTORY PATIENTS

<table>
<thead>
<tr>
<th>Trial ID</th>
<th>Page</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>18-311</td>
<td>p. 2</td>
<td>A multi-cohort phase 1b clinical trial of rituximab in combination with immunotherapy in untreated and previously-treated follicular lymphoma</td>
</tr>
<tr>
<td>17-313</td>
<td>p. 3</td>
<td>A phase 1b/2 trial of Hu5F9-G4 in combination with rituximab in patients with relapsed/refractory B-cell non-Hodgkin lymphoma. Hu5F9-G4 is a monoclonal antibody which is designed to block a protein called CD47, which is widely expressed on human cancer cells</td>
</tr>
<tr>
<td>18-322</td>
<td>p. 4</td>
<td>A phase 1b study of TAK-659 in combination with venetoclax for adult patients with previously treated non-Hodgkin lymphoma</td>
</tr>
<tr>
<td>18-608</td>
<td>p. 5</td>
<td>A phase 1/2a, open-label, dose-escalation, dose-expansion, parallel assignment study to evaluate the safety and clinical activity of PBCAR0191 in patients with relapsed/refractory (r/r) non-Hodgkin lymphoma and r/r B-cell acute lymphoblastic leukemia</td>
</tr>
</tbody>
</table>

See the following pages for more information about these trials.

These trials are offered through Dana-Farber/Harvard Cancer Center, an NCI-designated Comprehensive Cancer Center.
TRIALS FOR PATIENTS WITH RELAPSED/REFRACTORY DISEASE

18-311: A multi-cohort phase 1b clinical trial of rituximab in combination with immunotherapy in untreated and previously-treated follicular lymphoma

Rationale: This study is a phase 1b/2 study studying the efficacies of immunotherapies in newly diagnosed and relapsed follicular lymphoma patients. There will be three arms that will be open for enrollment: Rituximab, utomilumab (4-1BB agonist antibody) and avelumab (anti-PDL1 antibody); PF4518600 (Ox-40 agonist antibody), rituximab, and utomilumab; and rituximab, PF4518600, avelumab. Treatment is limited to 6 cycles for all arms. We are currently only open for relapsed follicular patients.

Key Eligibility Criteria:
- Histologically confirmed diagnosis of B-cell iNHL with histological subtype limited to FL Grade 1, Grade 2, or Grade 3a or Marginal Zone Lymphoma (MZL) nodal or extranodal, based on criteria established by the World Health Organization (WHO) 2016 classification.
- Patients can have had prior had CAR-T cell therapy or other genetically modified T-cell therapy
- Patients must be relapsed or refractory after 2 or more prior lines of therapy. One prior therapy must have included an anti-CD20 monoclonal antibody combined with an alkylating agent (single agent CD-20 antibody will not count as a line of therapy for eligibility)

Treatment Schedule:
Patients will be required to come into clinic 7 times during the first 28-day cycle, including a screening tumor biopsy along with an on-treatment biopsy. After the first cycle, patients will be required to come into clinic twice a month for their treatments for six months. Afterwards, they will be required to come to clinic once every 3 months.

Principal Investigator: Caron Jacobson, MD

Slots Available at Last Update: 14. Please email us for the latest information.

Follicular Lymphoma Clinical Trials, Dana-Farber/Brigham and Women’s Cancer Center. These trials are conducted through Dana-Farber/Harvard Cancer Center, an NCI-designated Comprehensive Cancer Center.
17-313: A phase 1b/2 trial of Hu5F9-G4 in combination with rituximab in patients with relapsed/refractory B-cell non-Hodgkin lymphoma. Hu5F9-G4 is a monoclonal antibody which is designed to block a protein called CD47, which is widely expressed on human cancer cells.

**Rationale:** This is a phase 1b/2 for relapsed/refractory DLBCL and indolent lymphomas (marginal zone and follicular lymphoma). This study is using rituximab in combination with Hu5F9-G4, an anti-CD47 drug. We are currently open with the combination arm with chemotherapy (RGemOx) + HuF59-G4 arm.

**Key Eligibility Criteria:**
- Patients must have had their last treatment either 3 weeks prior or 4 half-lives (up to a maximum of 4 weeks) whichever is longer
- Follicular lymphoma grade 1-3
- Patients cannot be transfusion dependent, requiring more than 2 units of RBC transfusions during the 4-week screening period

**Treatment Schedule:**
Patients will be required to have intensive treatment schedules during the first two months of treatment. The first cycle of treatment includes 8 visit dates. They will be coming in for treatment visits on 7 of those 8 dates this includes infusion of rituximab, Hu5F9-G4, gemcitabine and oxaliplatin. After the completion of the first cycle, the number of visits will decrease to 5 visits during cycle 2 and then three visits per month for 4 cycles. After the completion of cycle 4 patients will then transfer over to only receiving rituximab + Hu5F9-G4. Rituximab will be administered every other cycle from cycle 5 on. Patients will receive their first scan at the beginning of cycle 3 and their further treatment will be based upon that. Note: Patients must be willing to have the optional tumor biopsy done at pre-treatment and while on treatment.

**Principal Investigator:** Ann LaCasce, MD, MMSc

**Slots Available at Last Update:** Slots will vary. Please email us for the latest slot availability.

---

Follicular Lymphoma Clinical Trials, Dana-Farber/Brigham and Women’s Cancer Center.
These trials are conducted through Dana-Farber/Harvard Cancer Center, an NCI-designated Comprehensive Cancer Center.
**18-322:** A phase 1b study of TAK-659 in combination with venetoclax for adult patients with previously treated non-Hodgkin lymphoma

**Rationale:** This is a phase 1B, dose escalation study of TAK-659 in combination with venetoclax in adult patients with advanced non-Hodgkin lymphoma (NHL) after at least 1 prior line of therapy. The study’s primary objective is to determine the maximum tolerated dose (MTD) and/or the recommended phase 2 dose (RP2D) of TAK-659 and venetoclax when administered in combination. The study also looks to evaluate the safety and tolerability of TAK-659 and venetoclax when administered in combination. The TAK-659/venetoclax MTD/RP2D will be determined after consideration of safety data, preliminary pharmacokinetic (PK) data, and any early antitumor activity observed.

**Key Eligibility Criteria:**
- Patients must be aged 18 years or older with a confirmed diagnosis of advanced NHL of any histology (except CLL and MCL), including radiographically or clinically measurable disease
- Patients must be refractory or relapsed after 1 prior line of therapy, have no available effective standard therapy per investigator’s assessment; and be either treatment naïve to, relapsed/refractory to, or experienced treatment failure of ibrutinib, idelalisib or any other investigational B-cell receptor pathway inhibitor
- Patients must have an ECOG score of 0 or 1, adequate organ and coagulation function and life expectancy of greater than 3 months

**Treatment Schedule:**
Patients present to clinic following one of three TAK-659 dosing schemas, each seeking to dose escalate per patient’s response: Continuous daily dosing, 7 days on/7 days off, or 14 days on/7 days off. Please reach out to the study contact to confirm which TAK dosing schema has slot availability.

**Principal Investigator:** Matthew Davids, MD, MMSc

**Slots Available at Last Update:** Slots will vary. Please email us for the latest slot availability.
18-608: A phase 1/2a, open-label, dose-escalation, dose-expansion, parallel assignment study to evaluate the safety and clinical activity of PBCAR0191 in patients with relapsed/refractory (r/r) non-Hodgkin lymphoma and r/r B-cell acute lymphoblastic leukemia

Rationale: Allogeneic CAR-T product. No manufacturing required and 14-day consent to cells window.

Key Eligibility Criteria:
- The following types of lymphoma are included and must be confirmed CD19+ (biopsy can be within 6 months if no CD19 directed therapy was administered):
  - Diffuse large B cell lymphoma (DLBCL) including Richter's transformation
  - Primary mediastinal B-cell lymphoma (PMBL)
  - Follicular Lymphoma (FL) including grade 3B or transformed FL (TFL)
  - High-grade B-cell lymphoma
  - Small lymphocytic lymphoma (SLL)
  - Mantle cell lymphoma (MCL)
- Patient must have received at least 2 prior chemotherapy-containing regimens, one of which have contained an anthracycline and an anti-CD20 monoclonal antibody (unless the investigator determines that the patient’s tumor is CD20 negative)
- Adequate bone marrow, renal, pulmonary and cardiac (creatinine clearance >60 mL/min) (Platelet count ≥30,000) (AST and ALT ≤3 times upper limit of normal)
- Cannot have received stem cell transplant within 90 days before screening

Treatment Schedule:
Patients sign consent on Day -14, undergo conditioning chemotherapy on Days -5 to Day -3 and receive PBCAR0191 on Day 0. They are then seen in clinic for follow-up on Day 14, 28, 42, 60, 120, 150, 180, 270, and 360, where they will then be asked to sign-up for a long-term follow-up study.

Principal Investigator: Caron Jacobson, MD

Slots Available at Last Update: Slots will vary. Please email us for the latest slot availability.